Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Tarsus Pharmaceuticals, Inc.

Clinicaltrial registered21 Oct 2026

Tarsus Pharmaceuticals, Inc.

21 Oct 2026: Trial registered · A Study to Evaluate the Efficacy and Safety of TP-06 for PCED. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
21 Oct 2026
Title
A Study to Evaluate the Efficacy and Safety of TP-06 for PCED
Conditions
Persistent Corneal Epithelial Defect
Phase
Phase 2
Study Type
Interventional
Status
Recruiting
Countries
United States, Dominican Republic, El Salvador, Mexico
Country
United States
Reference
NCT07886268
Location
United States, Dominican Republic, El Salvador
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Tarsus Pharmaceuticals, Inc.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Across AOS Research

Other records for Tarsus Pharmaceuticals, Inc. in our registers.

More from United States

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.